SusanNChiMD

Pediatric Hematology & Oncology • Boston, MA

Pediatric Neuro-Oncology

Clinical Director, Pediatric Neuro-Oncology, Dana-Farber Cancer Institute/Boston Children's Hospital; Associate Professor of Pediatrics, Harvard Medical School

Join to view full profile

Dr. Chi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Chi's full profile

Already have an account?

Office
44 Binney St
Rm SW331
Boston, MA 02115
Phone+1 617-632-4142

Fax+1 617-632-4897

Summary

Dr. Susan Chi is a highly-qualified healthcare professional based in Boston, MA specializing in Pediatric Hematology & Oncology, with a subspecialty of Pediatric Neuro-Oncology. She initially trained in Pediatrics at Yale-New Haven Medical Center, then pursued fellowships in Pediatric Hematology/Oncology at Memeorial Sloan-Kettering Cancer Center/NY Presbyterian Cornell and Pediatric Neuro-Oncology at NYU. Since 2003, Dr. Chi has been practicing Pediatric Neuro-Oncology at the Dana-Farber Cancer Institute/Boston Children's Hospital. She has been involved in numerous experimental clinical trials and has a distinguished record of publications, including pivotal work on Atypical Teratoid Rhabdoid Tumor (ATRT) and other rare infant brain tumors. She has also contributed to the development of innovative treatments and to the establishment of new standards-of-care through the clinical trials she has led.

Education & Training

NYU Grossman School of MedicineFellowship, Pediatric Neuro-Oncology, 2001 - 2002
New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 1998 - 2001
Yale-New Haven Medical CenterChief Residency, Pediatrics, 1997 - 1998
Yale-New Haven Medical CenterResidency, Pediatrics, 1994 - 1997
Icahn School of Medicine at Mount SinaiClass of 1994
Princeton UniversityBA, 1990

Certifications & Licensure

ME State Medical License 2023 - 2026
RI State Medical License 2022 - 2026
CT State Medical License 1997 - 2025
MA State Medical License 2003 - 2025
NH State Medical License 2023 - 2025
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma Start of enrollment: 2018 Sep 24
Terminated
Phase 1, Phase 2
Roles: Contact
Fimepinostat in Treating Brain Tumors in Children and Young Adults Start of enrollment: 2019 Aug 07
Active, not recruiting
Early Phase 1
Roles: Contact, Principal Investigator
Preventative Skin Care for Children Undergoing Targeted CNS Tumor Therapy Start of enrollment: 2020 Oct 01
Active, not recruiting
Phase 2
A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion Start of enrollment: 2021 Apr 08
Recruiting
Early Phase 1
Roles: Contact, Study Chair
rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG Start of enrollment: 2022 Jan 10
Recruiting
Phase 1
Roles: Principal Investigator, Contact
MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma Start of enrollment: 2023 Apr 10
Recruiting
Phase 2
Roles: Contact
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021) Start of enrollment: 2020 Dec 09
Recruiting
Phase 1
Roles: Contact
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas Start of enrollment: 2019 Apr 03
Recruiting
Phase 1
Roles: Contact, Principal Investigator
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors Start of enrollment: 2023 Aug 10
Recruiting
Phase 1, Phase 2
Roles: Sponsor-Investigator, Contact, Principal Investigator
HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Start of enrollment: 2015 Sep 01
Active, not recruiting
Phase 4
Roles: Contact
ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma Start of enrollment: 2022 Dec 16
Recruiting
Phase 2
Roles: Contact
Combination Therapy for the Treatment of Diffuse Midline Gliomas Start of enrollment: 2021 Oct 20
Recruiting
Phase 2
Roles: Contact
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors Start of enrollment: 2022 Nov 21
Recruiting
Phase 1, Phase 2
Roles: Contact
Study of Ribociclib and Everolimus in HGG and DIPG Start of enrollment: 2024 Jun 28
Not yet recruiting
Phase 2
Roles: Contact
Study of Olutasidenib and Temozolomide in HGG Start of enrollment: 2024 Jun 01
Not yet recruiting
Phase 2
Roles: Contact
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults Start of enrollment: 2020 Oct 02
Recruiting
Phase 1
Roles: Contact
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion Start of enrollment: 2024 Sep 01
Not yet recruiting
Early Phase 1
Roles: Contact, Study Chair
Join now to see all

Publications & Presentations

PubMed

371 citations
Mechanisms and therapeutic implications of hypermutation in gliomas.
Mehdi Touat, Yvonne Y. Li, Adam Boynton, Liam F. Spurr, J. Bryan Iorgulescu
Nature. 2020-04-15
22 citations
Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C.
Susan N Chi, Joanna S Yi, P Mickey Williams, Sinchita Roy-Chowdhuri, David R Patton
Journal of the National Cancer Institute. 2023-11-08
25 citations
Revisiting the Role of Radiation Therapy for Pediatric Low-Grade Glioma
Danielle S. Bitterman, Shannon M. MacDonald, Torunn I. Yock, Nancy J. Tarbell, Karen Wright
Journal of Clinical Oncology. 2019-09-09

Press Mentions

EZH2 Inhibitor Shows Promise Among Children with Certain Solid TumorsFebruary 20th, 2018
What ‘Beans’ Taught Her Parents About Pediatric Cancer, the Need for Research, and Patient AdvocacyMarch 23rd, 2021